Keros Therapeutics has announced an important step in the development of Rinvatercept, an investigational treatment for Duchenne muscular dystrophy (DMD). The company reported on September 28, 2026, that the first patient has been dosed in its Phase 2 clinical trial evaluating Rinvatercept in people with DMD.
The company expects initial data from the trial in the first half of 2027. However, because Rinvatercept is still being studied, the trial is intended to determine whether the treatment is safe, tolerable, and potentially beneficial for people with DMD. It is not yet an approved treatment for DMD.
What Is Rinvatercept?
Rinvatercept is designed to influence biological signals involved in muscle and bone growth. It is a type of treatment called a ligand trap. The drug is designed to block the effects of two proteins, myostatin and activin A, which can limit muscle and bone growth.
According to Keros, blocking these signals may help support muscle regeneration, increase muscle size and strength, reduce fibrosis and inflammation, decrease fat accumulation, and improve bone health. These effects are part of the scientific rationale for studying Rinvatercept in DMD.
Earlier Phase 1 research in healthy volunteers also produced observations related to muscle mass, fat mass, and bone mineral density. These findings provided part of the basis for moving the program into Phase 2 clinical development.
What Will the Phase 2 DMD Trial Study?
The Phase 2 study, identified as NCT07704099, is an open-label, multi-cohort clinical trial. Its main objective is to evaluate the safety and tolerability of Rinvatercept in people with DMD. Read More: NCT07704099
The study is designed to include patients at different stages of disease progression, including late-ambulatory and early non-ambulatory patients. Researchers will also examine several other areas to understand how the treatment affects the body.
These include pharmacokinetics, which describes how a drug moves through the body, and anti-drug antibodies, which can indicate whether the immune system reacts to the treatment. The researchers will also evaluate body composition and functional measures involving skeletal muscle, motor function, the heart, and the lungs.
This broad approach is important because DMD affects more than walking ability. Muscle weakness can also affect respiratory function, cardiac health, body composition, and overall physical function.
Why Is This Trial Important?
DMD is a progressive genetic disorder that causes muscle weakness and affects multiple body systems. Although several treatment approaches are available or under development, researchers continue to investigate therapies that could address additional aspects of the disease.
Rinvatercept represents a different approach from therapies designed to restore dystrophin production. Instead, it aims to modify biological pathways involved in muscle and bone biology.
The Phase 2 study will provide important information about whether the biological effects observed in earlier research can translate into meaningful outcomes in people with DMD. However, the results will need to be carefully evaluated before conclusions can be drawn about its effectiveness.
For families following the DMD treatment pipeline, the next major milestone will be the clinical data expected in the first half of 2027. Until those results are available, Rinvatercept should be considered an investigational therapy rather than an established DMD treatment.
Clinical trial information can change as a study progresses, so patients and families should always check the official trial registry and discuss clinical-trial participation with their healthcare team.
